Clinical response to liposomal doxorubicin and rituximab in HHV-8-associated multicentric Castleman's disease in an HIV-positive patient

Morichika Osa; Takuya Maeda; Kazuhisa Misawa; Kazuo Imai; Yuji Fujikura; Akihiko Kawana

doi:10.1016/j.jiac.2016.06.004

Clinical response to liposomal doxorubicin and rituximab in HHV-8-associated multicentric Castleman's disease in an HIV-positive patient

J Infect Chemother. 2016 Dec;22(12):804-807. doi: 10.1016/j.jiac.2016.06.004. Epub 2016 Jul 1.

Authors

Morichika Osa¹, Takuya Maeda², Kazuhisa Misawa¹, Kazuo Imai¹, Yuji Fujikura¹, Akihiko Kawana¹

Affiliations

¹ Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan.
² Division of Infectious Diseases and Pulmonary Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan; Department of Microbiology, Saitama Medical University, Saitama, Japan. Electronic address: t_maeda@saitama-med.ac.jp.

PMID: 27373909
DOI: 10.1016/j.jiac.2016.06.004

Abstract

We report a patient with HIV-associated multicentric Castleman's disease who had recurrent human herpesvirus-8 viremia associated with intermittent febrile exanthema and lymphadenopathy. Although the patient relapsed after single-agent treatment with liposomal doxorubicin, weekly infusions of rituximab led to complete remission even though the reactivation of the Kaposi's sarcoma was unfortunately observed. Rituximab could not only eliminate the accumulation of HHV-8 load but also play a part in the modulation of dysregulated CD20-positive B cells in HIV-associated multicentric Castleman's disease.

Keywords: HHV-8; HIV; Liposomal doxorubicin; Multicentric Castleman's disease; Rituximab.

Publication types

Case Reports

MeSH terms

Aged
Castleman Disease / drug therapy*
Castleman Disease / virology
Doxorubicin / analogs & derivatives*
Doxorubicin / therapeutic use
HIV Infections / virology*
Herpesvirus 8, Human / drug effects*
Humans
Male
Polyethylene Glycols / therapeutic use
Rituximab / therapeutic use*

Substances

liposomal doxorubicin
Polyethylene Glycols
Rituximab
Doxorubicin

Supplementary concepts

Multi-centric Castleman's Disease